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INTRODUCTION 
 
The 3-Hydroxyl-3 methyl glutaryl Coenzyme A (HMG CoA) reductase 
inhibitors or statins have been a primary force in the management of 
hypercholesterolemia for many years and are important in the primary and 
secondary prevention of heart disease. However, increasingly it is being shown 
that the statins have clinical benefits that appear to be greater than those one 
would expect from improvement in the lipid profile alone. These pleotrophic 
actions include direct effects on vascular tissue, kidney, bone and glucose 
metabolism. 
The hyperinsulinaemic / insulin resistant states is a metabolic condition 
linked to widespread and heterogeneous clinical syndrome like hypertension, 
obesity, type-2 diabetes, dyslipidaemia, atherosclerosis and coronary vascular 
disease.  About 25% of the non-diabetic population shows abnormalities of 
insulin sensitivity and compensatory hyperinsulinaemia. 
Diabetes affected 194 million people worldwide in 2003 and is estimated 
to affect 299 to 333 million by 2025, according to International Diabetes 
Federation. 
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The South Asian population is known to be at risk of a atherosclerosis, 
even though the subject does not have clinical evidence of coronary heart 
disease.  
In India, population is vast, and there is heterogenecity of origin or race, 
geography and habit, socioeconomic status, dietary habits, methods of cooking 
and preservation, use of pesticides etc.  These factors along with known 
variables like age, sex etc. influence lipid profile of individuals. 
India is facing a diabetic explosion.  It has the world’s largest diabetic 
population about 25 million, and the number is predicted to rise to 35 million 
by 2010 and to 57 million by 2025.  The exact nature of the increase in 
prevalence of type 2 diabetes is unknown, and both genetic and lifestyle factors 
are being blamed. The urbanization tendency of rural India puts the incidence 
of diabetes with all its complications and mortality on the rise.  Insulin 
resistance is supposed to play a major role in the development of diabetes.   
Considering the magnitude and severity of hyperinsulinaemic / insulin resistant 
state, pharmaceutical measures are initiated early in an Indian. 
Clinical trials and animal studies (invivo and invitro) have shown that 
statins reduce cardiovascular disease risks and events, progression of 
nephropathy, development of diabetes and fracture rates, these are benefits that 
go beyond lipid lowering alone.   These agents improve insulin sensitivity and 
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reduce the likelihood of persons progressing from impaired glucose tolerance 
to type II diabetes. 
Various studies have observed the effect of statins on insulin sensitivity 
in Type 2 Diabetic mellitus.  Since statins are commonly used for the treatment 
of hypercholesterolemia in clinical practice, it is important to know their effect 
on insulin sensitivity. 
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AIMS AND OBJECTIVES 
 
 
 To evaluate the effects of Atorvastatin on insulin sensitivity. 
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REVIEW OF LITERATURE 
 
STATIN 
The statins (or HMG-CoA reductase inhibitors) form a class of 
hypolipidemic drugs used to lower cholesterol levels in people with or at risk 
of cardiovascular disease. They lower cholesterol by inhibiting the enzyme 
HMG-CoA reductase, which is the rate-limiting enzyme of the mevalonate 
pathway of cholesterol synthesis. Inhibition of this enzyme in the liver 
stimulates LDL receptors, resulting in an increased clearance of low-density 
lipoprotein (LDL) from the bloodstream and a decrease in blood cholesterol 
levels. The first results can be seen after one week of use and the effect is 
maximal after four to six weeks. 
Akira Endo and Masao Kuroda of Tokyo, Japan commenced research 
into inhibitors of HMG-CoA reductase in 1971 (Endo 1992). This team 
reasoned that certain microorganisms may produce inhibitors of the enzyme to 
defend themselves against other organisms, as mevalonate is a precursor of 
many substances required by organisms for the maintenance of their cell wall 
(ergosterol) or cytoskeleton (isoprenoids).  
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The first agent isolated was mevastatin (ML-236B), a molecule 
produced by Penicillium citrinum. The pharmaceutical company Merck & Co. 
showed an interest in the Japanese research in 1976, and isolated lovastatin 
(mevinolin, MK803), the first commercially marketed statin, from the mold 
Aspergillus terreus. Dr Endo was awarded the 2006 Japan Prize for his work 
on the development of statins. 
PATHWAYS OF ACTIVITY  
 
Cholesterol is required in maintaining cellular membrane structure and is 
also a precursor for the synthesis of steroid hormones and bile acid. The 
mevalonate pathway (FIGURE 1) is the series of biochemical reactions leading 
to the synthesis of cholesterol. The statins, by inhibiting HMG-CoA reductase, 
block the rate-limiting step in this pathway, resulting in decreased cholesterol 
production. Blocking cholesterol synthesis has been believed to be the statins' 
primary mechanism of action. However, a number of cholesterol-independent 
or pleiotropic effects of statins relate to their ability to block the synthesis of 
important intermediate products.  
Intermediate products in the mevalonate pathway include isoprenoids 
such as farnesylpyrophosphate and geranylgeranylpyrophosphate. The biologic 
mechanism for most of the pleiotropic effects of statins is related to inhibition 
of isoprenoid metabolism in nonhepatic cells (fig 1).1 The Ras family of 
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proteins is necessary for cellular differentiation and proliferation, while the 
Rho family is important for cytoskeleton formation, superoxide generation, and 
cell growth progression.1 Blocking these important isoprenoid intermediates 
affects mitochondrial respiration, lipid peroxidation, posttranslational 
modifications of cellular proteins, modifications of certain tRNA, and 
production of glycoproteins. Therefore, blocking of the mevalonate pathway by 
the statins may have significant influences on many critical cellular functions. 
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ACTIONS OF STATINS  
Statin therapy has been found to rapidly improve vasomotor response, 
enhance coronary blood flow, and reduce the levels of adhesion molecules. 
This is due in part to the ability of the statins to increase endothelial nitric 
oxide production secondary to inhibition of Rho and the resulting up-regulation 
of endothelial nitric oxide synthase (eNOS). Endothelial nitric oxide synthase 
is the enzyme required for nitric oxide production. Through another unclear 
mechanism, statins up-regulate the phosphatidylinositol 3'-kinase/Akt pathway 
(PI3-kinase/Akt pathway). This also activates eNOS (fig 2). The antioxidant 
effects of this group of drugs may also contribute to their ability to improve 
endothelial function.2 
 
Unstable atherosclerotic plaques are characterized by a lipid-rich core 
and excess inflammatory cells. The release of matrix metalloproteases by 
macrophages degrades plaque matrix connective tissue, weakening the fibrous 
cap. This makes these plaques susceptible to rupture. Statins have been shown 
to increase plaque stability by decreasing levels of metalloproteases, oxidized-
low density lipoprotein, core lipid content, macrophages, and by increasing the  
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collagen content in plaque matrix. Through the inhibition of Rho, lovastatin 
has been shown to increase tissue plasminogen activator activity while 
inhibiting plasminogen activator inhibitor type-1 activity. Thus, statins exert 
positive effects on the fibrinolytic profile in the vascular endothelium2. 
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Statins may exert anti-inflammatory effects by several pathways. The 
isoprenoids have been shown to activate inflammation via intracellular second 
messenger systems. Two other pathways include blocking the function of the 
integrin lymphocyte function-associated antigen-1 (LFA-1) and action on the 
phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Disruption of 
these pathways may inhibit lymphocyte recirculation, T-cell activation, and T-
cell migration. Other mechanisms yet to be fully elucidated may involve 
inhibition of adhesion molecules and inhibition of interleukins 6 and 8. High 
sensitivity C-reactive protein, a clinical marker of inflammation, is lower in 
hypercholesterolemic patients on statin therapy. 
Statins also affect gene expression.  Increased gene expression of bone 
morphogenetic protein-2 (BMP-2) through statin use resulted in increased bone 
formation in animal studies. This drug group has been demonstrated to inhibit 
the expression of class II major histocompatibility complex (MHC II) genes. T-
cell activation is dependent on interactions involving MHC. These findings 
indicate that statins may be effective as immunomodulators. In addition, in 
vitro studies with the HMG-CoA reductase inhibitors have demonstrated the 
suppression of natural killer cells, inhibition of chemotaxis by monocytes, 
regulation of DNA in cycling cells, and the inhibition of antibody-dependent 
cellular cytotoxicity. 
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Statins modify several processes in the cell cycle. They have been shown 
to synchronize tumor cells by blocking the transition of G1-S in the cell cycle, 
thereby exerting antiproliferative effects. This is thought to be secondary to the 
inhibition of geranylgeranylated proteins. The depletion of geranylgeranylated 
proteins also appears to mediate statin induced apoptosis. Ras inactivation is 
considered an important mechanism in the ability of statins to inhibit cell 
signaling pathways associated with the invasive and metastatic properties of 
cancer.   
 
PLEIOTROPIC EFFECTS OF STATINS : LIPID REDUCTION 
AND BEYOND 
 
IMPACT ON CVD  
 
Statins have been shown in primary and secondary prevention6 trials to 
significantly reduce fatal and nonfatal CVD events. Cardiovascular benefits of 
statins have been conventionally attributed to reduction of LDL-cholesterol. 
However, subanalyses of large clinical trials suggest that statins also have 
direct cardioprotective effects. For example, in WOSCOPS3, the time-to-event 
curves began to diverge within 6 months of initiating therapy, an effect that is 
earlier than predicted from cholesterol lowering alone. Clinical trials have also 
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shown larger significant CVD benefits associated with only minimal changes 
in luminal dimensions on angiography, benefits that cannot be explained by 
simple plaque regression . Statins also increase myocardial perfusion and 
reduce recurrent anginal episodes after acute coronary events. Potential 
mechanisms that may mediate these effects include modulation of endothelial 
function, plaque stabilization, attenuated atherogenesis, and anti-inflammatory 
and antithrombotic action3.  
STATINS AND PLAQUE STABILIZATION 
Most acute coronary events are due to disruption of unstable 
atherosclerotic plaques, which result in thrombotic occlusion. These vulnerable 
lesions occur in moderately stenotic vessels and are characterized by a lipid-
rich core and excess activated inflammatory cells . Macrophages release matrix 
metalloproteases that degrade plaque matrix connective tissue, weaken the 
fibrous cap, and render them susceptible for rupture . Statins have been shown 
to decrease the levels of metalloproteases, oxidized-LDL (ox-LDL), core lipid 
content, and macrophages and to increase collagen content in plaque matrix, 
actions that increase plaque stability2. 
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STATINS AND ENDOTHELIAL FUNCTION 
Statins have beneficial effects on vascular endothelium and many of 
these effects are mediated by the inhibition of small molecular weight G-
proteins of the Ras superfamily (Ras and Rho). These small molecular weight 
G-proteins are involved in cell proliferation, differentiation, apoptosis, 
migration, contraction, and regulation of gene transcription. Activated Ras/Rho 
proteins are key components in signal-transducing kinase cascades involved in 
NO production and glucose metabolism. Thus, inhibition of these proteins can 
critically affect various cellular processes. The anchoring of these small G-
proteins to cell membranes requires prenylation; Ras proteins are farnesylated, 
whereas Rho proteins are geranylgeranylated. Small G-proteins exist in an 
inactive GDP-bound cytosolic form, and upon cellular activation they 
exchange GTP and translocate to the active-membrane form (Fig.1). Lack of 
protein isoprenylation leads to cytosolic sequestration and loss of biological 
activity. Statins, in addition to lowering cholesterol by inhibiting HMG-CoA 
reductase enzyme, also reduce cellular isoprenoid intermediates such as 
dolichol, ubiquinone, farnesol, and geranylgeraniol (Fig.2). Statins, by 
inhibiting isoprenylation, effectively lower membrane levels and activity of 
Ras/Rho proteins and thus improve vascular function2. 
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Studies in humans and animals have demonstrated a positive effect of 
statins on endothelial function. Basal and stimulated endothelium-dependent 
forearm blood flow responses in hypercholesterolemic subjects are improved in 
4 wk of treatment with statins.. Simvastatin has been reported to increase 
endothelial NO production and improve NO-dependent vasorelaxation in 
different vascular beds . Chronic administration of simvastatin or mevastatin to 
rodents up-regulates endothelial NO synthase (eNOS) expression ,augments 
blood flow in cerebral vessels, and reduces infarct size . These studies suggest 
a direct action of the statins on NO production in the endothelium. 
Nevertheless, a major mechanism of action of statins in improving endothelial-
derived vasorelaxation is through LDL-cholesterol lowering. Indeed, acute 
lowering of LDL by apheresis has been shown to improve endothelium-
dependent vasodilatation in persons with hypercholesterolemia . 
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Figure 1.  Effects of statins on small G-proteins 
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Figure 2. 
 Cholesterol biosynthesis and mevalonate pathway. Bisphosphonates 
exert inhibitory effect a step distal to that of statins.  
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eNOS resides in the caveolae and produces small amounts of NO on 
demand in a transient fashion that is both calcium- and calmodulin-dependent. 
In the caveolae, eNOS is bound to the caveolar protein, caveolin that inhibits 
its activity. Elevations in cytoplasmic calcium promote binding of calmodulin 
to eNOS that subsequently displaces caveolin, thus activating eNOS (Fig.3). In 
addition to undergoing regulatory posttranslational modifications, eNOS is 
regulated by a serine-threonine kinase, Akt. Akt is activated by insulin/IGF-I 
binding to endothelial and vascular smooth muscle cells (VSMCs). 
Phosphorylation by Akt increases the affinity of eNOS to calmodulin and 
enhances the activity of eNOS. Statins activate Akt and thus increase NO 
production. Statins also decrease cellular caveolin levels and attenuate the 
inhibition of eNOS by caveolin, resulting in increased NO production. In 
addition to affecting posttranslational regulatory mechanisms, statins increase 
eNOS transcription, stability, and protein level. These class effects of statins 
contribute to improved NO-mediated vascular relaxation.  
Endothelial dysfunction is a hallmark of diabetes and insulin-resistant states 
and is characterized by reduced effective vascular NO action .  Statins 
ameliorate the abnormal vascular relaxation and partially restore NO 
production in the aorta of diabetic mice.   Hyperglycemic states both in vivo 
and in vitro stimulate Rho activity, which in turn activates Rho-kinase resulting 
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in increased vascular tone. The protective effect of statins on diabetic vascular 
disease may be due to the suppression of Rho kinase cascades, resulting in 
increased NO production and decreased vascular tone. Statins not only increase 
endothelial cell NO production but also up-regulate the inducible form of NOS 
(iNOS) in Vascular Smooth Muscle Cells. iNOS is expressed after vascular 
injury, and induction of iNOS in these states may be beneficial in preventing 
restenosis. 
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Figure 3:    Effects of statin on the endothelium. 
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Statins also modulate the release and action of vasoconstrictors          
(e.g. endothelin and angiotensin II). Clinical studies show that 
hypercholesterolemic men have exaggerated hypertensive responses to infused 
angiotensin II, and this response is reversed by statins . In a study using double 
transgenic rat model harboring the human renin and angiotensin genes, 
cervistatin improved survival, decreased blood pressure, and reduced cardiac 
hypertrophy . Statins also have a direct effect on endothelin-1 (ET-1) 
production (Fig.3). These agents reduce, in a dose- and time-dependent fashion, 
the expression of ET-1 in endothelial cells. This reduction is maintained even 
in the presence of ox-LDL. Because ET-1 is a powerful vasoconstrictor, 
decreasing ET-1 levels potentially reduces vascular resistance and improves 
blood flow in coronary and systemic vascular beds.  
THE ANTI-INFLAMMATORY ACTIONS OF STATINS 
The vascular inflammatory response is a complex process that leads to 
thrombus formation, angiogenesis, neointimal thickening, and atherosclerosis 
(4). Markers of inflammation such as C-reactive protein, IL-6, TNF-, and 
monocyte-chemotactic protein-1 (MCP-1) have, in varying degrees, been 
proposed as CVD risk factors. Recent evidence indicates that statins decrease 
C-reactive protein levels in just 6 wk of treatment, independent of LDL 
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cholesterol reduction, and suggests that statins possess anti-inflammatory 
actions.  
Augmented expression of adhesion molecules on leukocytes               
(e.g. CD11b) and endothelial cells (e.g. P-selectin, intracellular adhesion 
molecule, ICAM-1) is necessary and critical in the early vascular response to 
injury. Cytokines, in addition to enhancing cellular adhesion, promote 
chemotaxis and stimulate vascular proliferation. Statins affect many of these 
events in the inflammatory cascade by inhibiting receptor-dependent activation 
of signal-transducing cascades. In a rat model of coronary inflammation, 
pravastatin reduces MCP-1 expression, monocyte infiltration, and proliferation. 
Simvastatin reduces leukocyte rolling, adherence, and transmigration in a 
rodent model of NO deficiency and attenuates endothelial adhesion molecule 
and monocyte CD11b expression in the absence of lipid lowering (Fig.4). 
Statin therapy reduced the levels of soluble P-selectin in patients with acute 
coronary syndromes. In another rat model associated with elevated serum 
levels of TNF- and IL-1ß, cerivastatin has been shown to reduce serum levels 
of these markers and improve survival rate. Statins also mediate the 
suppression of cytokine and adhesion molecule expression by reducing NFkB 
activity in inflammatory and vascular cells. These observations underlie the 
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importance of statins in attenuating the inflammatory process and the 
consequent impact on CVD risk reduction8.  
STATINS AND OXIDATIVE STRESS  
 
Oxidative stress is a result of altered balance in the relative 
concentrations of oxidants and antioxidants. Ox-LDL is deleterious to 
endothelial and Vascular Smooth Muscle Cells. It activates macrophages, 
induces release of various cytokines, and increases endothelial adhesiveness 
resulting in vascular injury and inflammation. Statins as potent antioxidants and 
antiatherosclerotic agents are attractive therapeutic options for preserving 
normal vascular function and blood flow. In several human and animal studies, 
various statins have been shown to: 1) inhibit the uptake and generation of ox-
LDL4, 2) attenuate vascular and endothelial superoxide anion formation by 
inhibition of NADH oxidases via Rho-dependent mechanisms4; and 3) preserve 
the relative levels of vitamin E, vitamin C, and endogenous antioxidants such 
as ubiquinone and glutatione in LDL particles4. Thus, statins not only decrease 
oxidants but also restore antioxidants, thereby possibly reducing the level of 
oxidative stress in the vascular milieu, which may explain some of the observed 
clinical beneficial effects.  
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STATINS AND THROMBOSIS 
Different statins have varying effects on prothrombotic factors, such as 
tissue factor, tissue factor pathway inhibitor, platelet aggregation, blood and 
plasma viscosity, fibrinogen, plasminogen activator inhibitor 1 (PAI-1), and 
lipoprotein (a)4. Cellular expression of tissue factor in human macrophages is 
suppressed by lipophilic statins. Statins normalize thrombin generation in 
hypercholesterolemic patients and reduce platelet aggregation. Furthermore, 
decreases in platelet aggregation after statin therapy may be partially related to 
relative reductions in the cholesterol to phospholipid content in the platelet 
membrane.  
STATINS AND VASCULOGENESIS 
Statins, in addition to modulating endothelial and vascular function, may 
mediate neovascularization (vasculogenesis) and collectively contribute to the 
reduction in recurrent CVD events. Increased vasculogenesis has been 
demonstrated in rabbits treated with simvastatin via the activation of vascular 
Akt4. Statins mobilize endothelial progenitor cells (EPCs) from the bone 
marrow that play a role in maintenance vasculogenesis. Increased EPCs are 
seen immediately after a coronary event and line the endothelium of 
myocardial vessels. Indeed, statin therapy is associated with enhanced EPCs in 
patients with coronary artery disease4.  
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STATINS AND KIDNEYS  
Statins have been shown to attenuate renal injury in both in vivo and in 
vitro studies. Renal injury initiates inflammatory cascades that involve similar 
cellular events as seen in vascular tissue.   Statins inhibit key events in this 
process that alter the progression of renal injury. In hyperglycemic insulin-
deficient diabetic rats, pravastatin ameliorates the structural and functional 
changes of diabetic nephropathy13.  Statins have been demonstrated to decrease 
TGF-ß production and suppress the enhanced Ras-dependent activation of 
MAPK cascade (Fig.4). In another model of renal injury due to overexpression 
of Ang II, cerivastatin decreased systolic blood pressure, albuminuria, and 
cortical necrosis. These changes were associated with reduced infiltration of 
inflammatory cells, diminished expression of adhesion molecules, and lower 
levels of transcription factor (NFkB) activity (Fig.4). In rats with 
glomerulonephritis, simvastatin decreased mesangial cell proliferation and 
monocyte/macrophage infiltration.   
Statins have been shown to inhibit the proliferative actions of platelet-
derived growth factor and TGF-ß. Cytokines released during renal injury 
activate NF-B and growth-regulating pathways in mesangial and tubular cells.  
Statins both decrease the levels of cytokines and inhibit the NF-B-dependent 
gene activation, such as MCP-1 and IL-6.   In humans, statins also decrease 
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urinary albumin excretion in patients with nephrotic syndrome and in patients 
with type II diabetes4.  Thus, statins modulate glomerular mesangial and 
interstitial inflammatory process independent of lipid reduction.  
STATINS AND GLUCOSE METABOLISM  
A retrospective analysis of the WOSCOPS examining the development 
of new diabetes mellitus revealed that pravastatin therapy reduced the risk of 
developing diabetes by 30%. This prevention in the onset of diabetes was 
associated with significant reduction in triglyceride levels, but upon further 
analyses the reduction in triglycerides did not account for the effect of statins 
on the development of diabetes14.  
Statins may affect substrate delivery to insulin-sensitive tissues or 
modulate insulin-activated signaling cascades that mediate glucose uptake. 
Insulin increases skeletal muscle perfusion and substrate delivery by enhancing 
eNOS activity. As described previously, statins also increase eNOS expression, 
which may result in increased capillary recruitment and glucose disposal . 
Insulin activates a series of kinase cascades that involve PI3K and Akt, 
resulting in the translocation of glucose transporters to cell membrane and 
enhanced glucose uptake. This cascade is inhibited by circulating cytokines 
(TNF- and IL-6).  
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Statins, like insulin, activate PI3K and Akt, which may play a role in 
glucose uptake. Statins, in addition to decreasing cytokine levels, also inhibit 
the cellular cascades such as Rho-kinase that inactivate the insulin receptor and 
signaling. NO is a potential intermediary, because it has been shown to 
stimulate skeletal muscle glucose uptake .  
There is also evidence that statin mediated effects on fatty acid 
metabolism influence glucose metabolism. The peroxisome proliferator 
activator protein receptors are known to known to be major regulators of intra 
and extracellular fatty acid metabolism, especially PPAR alpha (5). PPARs 
belong to the superfamily of nuclear receptors that are ligand activated 
transcription factors. 
There is preliminary evidence that PPAR alpha activation would also 
result in improved insulin sensitivity.  A possible mechanism for this PPAR 
alpha activation is the statin induced inhibition of Rho, which results in PPAR 
alpha  activation. This raises the possibility that atorvastatin positively affects 
insulin sensitivity and help to prevent transition from impaired glucose 
tolerance to manifest type 2 diabetes. 
Inflammatory markers linked with insulin resistance is associated with 
the development with type 2 diabetes in adults. The mechanism by which 
inflammation leads to glucose intolerance and diabetes is not known, but 
 27
proinflammatory cytokines may affect insulin receptor or impair insulin action 
and secretion(11). 
In the WOSCOPS study ,pravastatin was found to produce 30% 
reduction in the risk of diabetes.The possible roles of pravastatin  in the 
development of diabetes are  
1. The triglyceride lowering effect of pravastatin could reduce the 
risk of developing insulin resistance. But other lipid lowering 
agents do not appear to improve insulin resistance.3. 
2. Pravastatin has been shown to reduce levels of interleukin 6 and 
TNF –a through its anti - inflammatory effects. These  cytokines  
are known to inhibit lipoprotein lipase activity and to stimulate 
lipolysis in adipose tissue . Pravastatin may therefore interrupt the 
progression from central obesity to insulin resistance mediated by 
adipose tissue – derived cytokines. 
3. Impaired endothelial function has been shown to correlate with 
insulin resistance. Pravastatin, by restoring endothelial function, 
may beneficially affect glucose and insulin transport.     
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Figure 4.   Effects of statins on inflammation and glucose metabolism 
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STATINS AND CHOLESTEROL 
Insulin resistance and type 2 diabetes are associated with high 
triglyceride and low HDL-cholesterol levels. Increased synthesis of VLDL 
particles in the liver has been proposed the main cause of increased 
concentrations of triglyceride-rich lipoproteins. This overproduction of VLDL 
and triglycerides in the liver has been proposed to be driven by high levels of 
serum free fatty acids in patients with insulin resistance. 
Insulin resistance could explain the increase in cholesterol synthesis in 
patients with obesity and type 2 diabetes6 .This hypotheses is supported by the 
finding that in subjects with normal glucose tolerance, high glucose is linked to 
increased cholesterol synthesis. Increased cholesterol synthesis is always 
accompanied by low rates of cholesterol absorption. Therefore insulin 
resistance is associated with high cholesterol synthesis and cholesterol 
absorption. Because fasting insulin correlated with cholesterol synthesis 
independent of the rates of BMI and whole body glucose uptake, it is possible 
that regulation of cholesterol synthesis by hyperinsulinemia may be a link 
between insulin resistance and cholesterol metabolism7. 
Various studies have shown that insulin sensitizing effect of statins may 
be linked to their triglyceride lowering effect. 
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STATINS AND BONE REMODELING  
 
Statins were also shown to stimulate bone formation in several studies. 
In vitro, statins increase the number of osteoblasts and the amount of new bone 
formation in mouse skull bones. Similar effects were also seen in vivo when 
simvastatin or lovastatin was injected subcutaneously over the skull bone of 
mice. Furthermore, oral administration of simvastatin to rats increased 
trabecular bone volume and the rate of new bone formation. These findings 
were confirmed by further studies; for example, transdermal lovastatin and 
cerivastatin were shown to increase bone mass in rodents at doses similar to the 
dose used in humapins in the treatment of hypercholesterolemia .All of these 
findings illustrate positive effects of statins on bone remodeling in the form of 
inhibition of bone resorption and stimulation of bone formation.  
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MATERIAL AND METHODS 
 
SELECTION OF VOLUNTEERS 
The study deals with the effect of Atorvastatin on insulin sensitivity 
conducted at Hypertension outpatient department of Government Stanley 
Medical College Hospital, Chennai. Ethical approval for the study was 
obtained from the institutional ethical review board.  Ninety patients are 
screened for the study from a random population of 110 hypertensive patients 
receiving atenolol as anti-hypertensive drug, by a random selection process, 
from which 68 patients are considered based on patient compliance, 
intelligence to understand dietary prescriptions and directions and whether free 
from any other disease on initial medical testing.  Written consent for the study 
as per protocol is obtained.  
The patients were randomized into two groups, of 34 patients each, by a 
random selection process. The experimental group consisting of 34 
dyslipidaemic and hypertensive patients receiving atorvastatin 10mg/day and 
atenolol 50 mg/day  at the Hypertension OPD at Govt Stanley Medical College 
Hospital are chosen as volunteers and are compared with another group of 34 
hypertensive patients receiving atenolol 50 mg/day only.  Uniform diet pattern 
is prescribed to all of them. 
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INCLUSION CRITERIA 
Dyslipidaemia, Hypertension, Age 40 to 50 years, not receiving any 
drugs other than mentioned above, not suffering from any other diseases. 
EXCLUSION CRITERIA  
Those patients not satisfying the inclusion criteria are excluded. 
CLINICAL CHARACTERS OF VOLUNTEERS  
Clinically, both the groups show no abnormality, other than hypertension 
in both groups, along with dyslipidaemia in the experimental group.  
DATA COLLECTION  
Height, Weight, BMI and blood pressure measurements were done and 
other information collected with the help of predesigned questionnaire. 
BIOCHEMICAL PARAMETERS  
Fasting blood sugar, fasting insulin, fasting lipid profile (cholesterol, 
triglyceride, HDL, LDL) were done by the standard methods. 
Other parameters like liver function tests (LFT), total leukocyte count 
(TLC), differential leukocyte count (DLC), haemoglobin (Hb), urea, creatinine, 
total proteins, serum electrolytes, urine tests, electro-cardiograph (ECG), X-ray 
of  chest, etc. are almost identical and within normal range in both the  groups. 
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COLLECTION OF BLOOD SAMPLES 
Twelve hours fasting values are taken initially and at monthly intervals 
for 1 year.  
ASSESSMENT OF INSULIN SENSITIVITY 
 
Insulin sensitivity was assessed by calculating Homeostasis model 
assessment (HOMA –IR) as follows : 
       Fasting Insulin µ/ml  x Fasting Glucose mg/dl 
22.5 
STATISTICAL METHODS  
The statistical analysis is done based on paired t-test, and p-value is 
calculated using paired t-statistic.  
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RESULTS AND OBSERVATIONS 
 
Table – 1 shows the anthropometric and biochemical characteristics of 
the subject in the control and Atorvastin treated groups at the start of the study.  
The proportion of the male & female in both the groups was similar.  
Proportion of subjects having positive family history of diabetes and blood 
pressure in both the groups were also similar. 
It is found that in the group receiving atenolol and atorvastatin 
(experimental group), TC is reduced from initial values of 280 +/- 20 mg/dl to 
202 +/- 12 mg/dl   (p = 0.05). HDLC is increased from 45 +/-10 mg/dl to 52 +/-
12 mg/dl (p = 0.04). LDLC reduced from 180 +/-20 mg/dl to 148 +/-12 mg/dl 
(p = 0.05). VLDLC, Triglycerides values remain almost same, and changes are 
statistically insignificant. FBS values changed from initial 106 +/- 6 mg/dl to 
88 +/-4 mg/dl (p = 0.04).  
In the control group receiving atenolol only, it is observed that TC is 
from initial values of 140 +/-20 mg/dl to 112+/-8 mg/dl. HDLC changes from 
40 +/-10 mg/dl to 44 +/-9 mg/dl. LDLC changes from 110 +/-30 mg/dl to 95 
+/-13 mg/dl. VLDLC, TG and FBS values remain almost same, and all the 
value changes are statistically insignificant. Table 4 shows serum insulin and 
homeostasis model assessment of insulin resistance (HOMA 2-IR) values of 
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different groups, in order to determine insulin sensitivity. It was observed that 
in the experimental group, serum insulin value initially is 20 +/-5 microU/ml 
and finally is 18 +/-3 microU/ml (p = 0.03), and in the control group, serum 
insulin value initially is 18 +/-5 microU/ml and finally is 31 +/-2 microU/ml. 
HOMA 2 values (insulin resistance or IR) of the two groups of patients show 
that in the experimental group it was 4.3 +/-0.5 microU/ml initially and 4.3 +/-
0.3 microU/ml finally, showing increase in  insulin sensitivity by atorvastatin. 
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Table 1:    Anthropometrical, Clinical and  Biochemical characters of 
volunteers 
 
  
Experimental 
Group  (34) Control Group (34) 
Age 45 ± 4 43 ± 3 
Males 21 21 
Females 13 13 
BMI 27.3 ± 12 27.5 ± 2.1 
SBP 154 ± 16 146 ± 24 
DBP 100 ± 12 94 ± 8 
T. Cholesterol 280 ± 20 140 ± 20 
LDL 180 ± 20 110 ± 20 
HDL 45 ± 10 40 ± 10 
VLDL 40 ± 5 35 ± 15 
TGL 220 ± 20 120 ± 20 
FBS 106 ± 6 96 ± 6 
Fasting Insulin 20 ± 5 18 ± 5 
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    Table 2:         Values of Blood parameters of Experimental Group  
  
0 mon 1 mon 2 mon 3 mon 4 mon 5 mon 6 mon 7 mon 8 mon 9 mon 10 mon 11mon 12 mon 
T. 
cholesterol 2.80 ± 20 276 ± 18 270 ± 16 260 ± 15 256 ± 16 248 ± 18 240 ± 16 234 ± 12 226 ± 11 218 ± 13 212 ± 12 208 ± 10 202 ± 12 
HDL 45 ± 10 45 ± 12 46 ± 12 46 ± 13 47 ± 12 48 ± 16 48 ± 8 49 ± 11 50 ± 14 50 ± 10 51 ± 13 51 ± 11 52 ± 12 
LDL 180 ± 20 178 ± 18 17 ± 12 172 ± 11 172 ± 12 168 ± 18 166 ± 10 164 ± 8 160 ± 12 160 ± 8 158 ± 10 152 ± 8 148 ± 12 
VLDL 40 ± 5 40 ± 3 40 ± 2 39 ± 6 39 ± 5 39 ± 6 39 ± 5 39 ± 4 39 ± 2 39 ± 4 39 ± 3 39 ± 4 39 ± 3 
TGL 220 ± 20 218 ± 18 218 ± 16 214 ± 10 214 ± 8 216 ± 8 212 ± 10 210 ± 11 210 ± 12 206 ± 6 214 ± 8 208 ± 8 212 ± 6 
FBS 106 ± 6 106 ± 5 105 ± 3 103 ± 4 103 ± 3 101 ± 4 98 ± 5 98 ± 6 96 ± 5 93 ± 4 92 ± 5 90 ± 3 88 ± 4 
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Table 3:              Values of Blood parameters of Control Group 
 
 
 
 
 
  
 
                
 
       
  
0 mon 1 mon 2 mon 3 mon 4 mon 5 mon 6 mon 7 mon 8 mon 9 mon 10 mon 11 mon 12 mon 
T. cholesterol 140 ± 20 138 ± 8 136 ± 16 134 ± 15 132 ± 15 130 ± 16 128 ± 8 125 ± 10 123 ± 8 120 ± 12 117 ± 6 115 ± 6 112 ± 18 
HDL 40 ± 10 40 ± 8 41 ± 9 41 ± 7 41 ± 5 42 ± 6 42 ± 7 42 ± 7 42 ± 6 43 ± 8 43 ± 9 43 ± 8 44 ± 9 
LDL 110 ± 30 110 ± 12 108 ± 18 108 ± 16 108 ± 14 106 ± 12 106 ± 13 106 ± 13 102 ± 11 100 ± 18 98 ± 16 97 ± 10 95 ± 13 
VLDL 35 ± 15 35 ± 9 35 ± 8 35 ± 7 35 ± 8 35 ± 10 35 ± 10 35 ± 8 35 ± 12 35 ± 14 35 ± 11 35 ± 6 35 ± 8 
TGL 120 ± 20 120 ± 11 120 ± 8 119 ± 12 120 ± 14 118 ± 12 119 ± 8 116 ± 15 118 ± 8 118 ± 11 110 ± 12 
116 ± 
12 116 ± 13 
FBS 96 ± 10 96 ± 8 94 ± 6 94 ± 5 92 ± 8 94 ± 8 94 ± 5 92 ± 6 92 ± 9 92 ± 8 96 ± 7 94 ± 8 94 ± 6 
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Table 4: Showing serum insulin and HOMA-IR 2 values of Different group 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
S. insulin 
initial 
value 
S. insulin 
end value 
Homeostasis model 
assessment of insulin 
resistance 2-IR  
(initial value) 
HOMA - 2 IR end 
value 
Exp Group 20 ± 5 18 ± 3 4.3 ± 0.5 3.7 ± 0.4 
Control Group 18 ± 5 18 ± 5 4.3 ± 0.3 4.3 ± 0.2 
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Comparison of different variables between experimental groups and Control Groups 
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DISCUSSION 
 
The study shows that atorvastatin increases insulin sensitivity in normal 
subjects. Compared with placebo, treatment with atorvastatin (10 mg/day) 
resulted in significant reduction in the HOMA index. In addition, significant 
reductions in total and LDL cholesterol concentrations were observed in the 
atorvastatin group. It thus corroborates previous findings that though uncertain, 
statin therapy can affect insulin resistance syndrome.14. 
Insulin Resistance refers to the reduction in insulin mediated glucose 
uptake in insulin sensitive tissues, specifically in the skeletal muscles.  As a 
compensatory response, hyperinsulinemia ensures to maintain normal blood 
glucose levels.  In epidemiological studies, fasting insulin level is commonly 
used as a surrogate marker of insulin resistance.14. 
In normoglycemic subjects, fasting insulin correlated well with whole 
body glucose uptake. Although fasting insulin is a reasonable measure of 
insulin resistance, it is potentially confounded by variability in insulin 
secretion.  Thus the indexes derived from fasting insulin and glucose, such as 
Homeostasis Model Assessment (HOMA), the Quantitative Insulin Sensitivity 
Check Index (QUICKI), and the Insulin Sensitivity Index (ISI) developed by 
Gutt and coworkers, have been more widely used to assess insulin resistance in 
clinical and population based studies. 
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Although the role of insulin resistance in the pathophysiology of type 2 
diabetes mellitus is well accepted, the relationship between insulin resistance 
and blood pressure remains controversial.  Nearly 40 years ago, Welborn and 
colleagues observed that non diabetic patients with essential hypertension had 
significantly higher plasma insulin concentrations than did normotensive 
individuals. 
Statins are the more effective LDL – cholesterol-lowering drugs by 
about 25% to 60%. In addition, they also increase HDL-cholesterol by about 
5% to 10% and decrease triglycerides by about 10% to 30%. The effect on 
triglycerides is proportional to the decrease in LDL-cholesterol. Pre diabetes 
and  type 2 diabetes are characterized with low grade inflammation. Aggressive 
lowering of LDL-cholesterol by atorvastatin decreases hsCRP by 42% vs 9.6% 
with placebo. Several studies have proved that LDL-reduction by statins is 
associated with improved endothelial function due to enhanced NO 
release.Besides these actions ,the reduction in risk of development of diabetes  
is due to improved insulin sensitivity by statins.12 
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Okyima et. al  suggest that statins could have some impact on insulin 
action, and, to estimate the direct effects of statins on insulin secretion from 
pancreatic beta cells, MIN6 cells were treated with pravastatin, simvastatin or 
atorvastatin. Basal insulin secretion at low glucose concentration was 
unexpectedly increased at very high doses of simvastatin or atorvastatin after 
24 and 48 hours of incubation, though insulin secretion was apparently 
decreased by these lipophilic statins.18. 
Yoshitomi et al. assessed the relationship between IR and the changes of 
lipid profile in patients with hyperlipidaemia treated by atorvastatin. The IR did 
not affect the degree of reduction in cholesterol by atorvastatin in non-diabetic 
subjects. The IR may influence hypertriglyceridaemia greater than the effect of 
atorvastatin in non-diabetic subjects.20 
It has been suggested that HMG Co-A reductase inhibitors (‘statins’) 
may reduce the risk of developing type 2 Diabetes mellitus. Yee et al.  
designed to evaluate whether use of statins would also delay progression to 
insulin therapy. After multivariate adjustment, however, statin use was 
associated with a 10-month delay before newly treated diabetic subjects needed 
to start insulin treatment.21 
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Poalisso G et al. observed that statins administration was associated with 
an improvement of insulin resistance and decline in plasma triglyceride 
concentrations. 
This study suggest that statins increase insulin sensitivity even in 
normoglycemic patients. 
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CONCLUSION 
 
1. Statins improve insulin sensitivity even in normoglycemics and 
prevent the progression of IGT to  type 2 diabetes. 
2. Statins reduce levels of interleukin 6 and TNF through its anti-
inflammatory activity.  These cytokines inhibit lipoprotein lipase 
activity and to stimulate lipolysis in adipose tissue.  Atorvastatin may 
therefore interrupt the progression from central obesity to insulin 
resistance mediated by the adipose tissue derived cytokines. 
3. Impaired endothelial function has been shown to correlate with insulin 
resistance. Atorvastatin by restoring endothelial function, may 
beneficially affect glucose and insulin transport. 
4. Since statins are used for the treatment of hypercholesterolemia in 
clinical practice, it is important to know their effect on insulin 
sensitivity.  If further studies confirm the observation that statins 
improve insulin sensitivity and reduce the onset of type 2 diabetes, the 
perceived benefit of cardiovascular intervention in clinical trials could 
be greatly increased and the long term cost-benefit analysis of those 
interventions may be more positive than previous studies have 
estimated. 
 52
BIBLIOGRAPHY 
1. Mcfarlane S et al. Pleotropic effects of statins: Lipid reduction and 
beyond. Journal of clinical endocrinology 2002;879(4); 1451-1458 
2. Wolfrum et al. Endothelium dependent effects of statins . Arterioscler 
Thromb   Vasc  Biol;2003;23(5).729-736 
3. Freeman et al. Pravastatin  and development of diabetes.West of 
Scotland Coronary   Prevention Study .Circulation.2001;103;(3);357-362 
4. Ikeda et al. Pleotropiceffects of statins on vascular tissue. Current Drug 
Targets Cardio Haematology Disorder.2001;1(1);51-58 
5. Waldman et al . Pleotropic effects of  statins. Drugs. 2003;63(2);139-152 
6. Shepherd et al.Prevention of coronary artery disease with pravastatin in 
hypercholesterolemia.1995 NEJM303.1301-1307. 
7. Tonolo et al .Additive effects of simvastatin beyond its effect on 
LDLcholesterol  in hypertensive type 2 diabetic patients.2000 Eur J Clin 
30;980-987 
8. Tedgui et al .Anti-inflammatory mechanisms in vascular 
wall.Circulation.   2001.88:877 – 887 
9. Perticone et al. Effects of atorvastatin on endothelial function of    
hypercholesterolemia. Atherosclerosis 2000. 152; 511-518. 
 53
10. Mcfarlane et al.  Insulin resistance and cardiovascular disease.Journal of  
Clinical Endocrinology  2001. 86; 713-718. 
11.Jialal et al.Effect of statin on high sensitive Creactive protein. 
Circulation.2001. 103; 1933-1935. 
12.Albert et al.Effect of Statins on C-reactive protein. PRINCE trial  
JAMA2001.286; 64-70 
13.Yokota et al. Mechanism of preventive effect of statins on diabetic 
nephropathy. Kidney International journal. 1999; 71; 178-181. 
14.Recent advances in our understanding of insulin action and insulin 
resistance.   Le Roith et al. Diabetes Care.2001.24;503-508. 
15.Gill et al.Difficult diabetes. Oxford ;Blackwell science ;2001 
16. King et al.Global burden of diabetes. Diabetes care.1998.21(9).1414-31. 
17.Parhoefer et al. Atorvastatin aids insulin sensitivity in metabolic 
syndrome. American journal of Cardiology2006;98;66-69. 
18.Okajima et al. Effects of statins on insulin secretion from a beta cell line, 
MIN6 cells.Atheroscler Thromb 2006.13(6);329-335. 
 54
19. Takono et al. Effects of statins on glucose tolerance in type 2 diabetes 
mellitus.AtheroscleroThromb 2006.13(2);95-100. 
20.Yoshitomi et al .Relationship between insulin resistance and effect of 
atorvastatin in nondiabetic subjects. Atherosclero Thrombosis.2005; 
12(1);   9-13. 
21.Yee et al. Statin use in type 2 diabetes is associated with a delay in 
starting insulin.Diab Med. 2004.21(9);962-7. 
22.Jick et al.Statins and newly diagnosed diabetes. British journal of clinical 
pharmacology. 2004; 58(3); 303-9. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 55
PROFORMA 
 
 
Data collected from the participants 
Name :                   Age :          Sex :         Occupation :                
Address :                                                    Weight 
 
BMI     
SBP     
DBP     
Hb     
TC     
DC     
Urea     
Creatinine     
Electrolytes     
LFT     
T.Proteins     
Urine analysis     
ECG     
X-ray chest     
T.Cholesterol     
LDL-C(mg/dl)     
HDL-C(mg/dl)     
VLDL-C(mg/dl)     
TGL(mg/dl)     
FBS     
S.Insulin     
 
S.No. Name BMI
T.cholesterol 
mg/dl
LDLC 
mg/dl
HDLC 
mg/dl
VLDLC 
mg/dl
TGL 
mg/dl
FBS 
mg/dl
S.insulin 
µU/ml
1 Munusamy 48 / m 26 156 / 100 282 194 48 42 210 105 21
2 Muthu 45 / m 25 160 / 90 285 202 42 46 215 109 20
3 Krishnan 46 / m 23 150 / 110 274 203 41 50 200 98 21
4 Pasupathy 49 / m 24 160 / 100 281 196 39 48 216 102 19
5 Moorthy 46 / m 27 152 / 90 292 194 49 38 215 108 19
6 Benjamin 46 / m 26 162 / 100 271 188 45 44 220 110 20
7 Murugesan 49 / m 26 156 / 90 282 192 44 40 202 98 18
8 James Raja 48 / m 24 160 / 100 275 201 40 46 216 108 22
9 Kalimuthu 45 / m 23 162 / 98 282 192 42 38 218 102 21
10 Ganesan 44 / m 26 166 / 92 268 206 48 36 226 95 19
11 Subbiah 49 / m 24 154 / 90 272 188 42 46 208 97 20
12 Karupiah 45 / m 24 152 / 94 284 202 51 48 220 101 18
13 Rajendran 46 / m 23 160 / 90 268 196 41 52 211 110 19
14 Kuppusamy 49 / m 25 156 / 96 288 188 42 56 210 106 21
15 Ramachandran 48 / m 20 162 / 96 288 192 48 42 206 98 20
16 Lakshmi 49 / F 24 150 / 90 276 182 47 38 210 92 21
17 Kamalammal 49 / F 24 154 / 90 276 196 46 48 217 102 20
SBP/DBP 
mmhg
Age/Sex
MASTER CHART  - EXPERIMENTAL GROUP
S.No. Name BMI
T.cholesterol 
mg/dl
LDLC 
mg/dl
HDLC 
mg/dl
VLDLC 
mg/dl
TGL 
mg/dl
FBS 
mg/dl
S.insulin 
µU/ml
SBP/DBP 
mmhg
Age/Sex
18 Vijaya 46 / F 26 160 / 90 280 201 48 52 210 105 21
19 Saroja 47 / F 21 154 / 96 296 190 48 48 216 109 20
20 Vasanthi 49 / F 24 160 / 100 274 188 46 38 198 108 21
21 Rajeswari 48 / F 24 150 / 110 278 196 49 36 202 102 19
22 Pushpa 45 / F 26 152 / 100 281 195 52 38 196 108 19
23 Jaya 44 / F 23 156 / 90 284 199 51 44 192 110 20
24 Dayalan 46 / m 24 162 / 110 278 192 46 46 204 102 18
25 Egambaram 48 / m 25 158 / 74 276 204 48 42 201 108 22
26 Munirajan 46 / m 27 164 / 90 284 203 46 42 197 92 21
27 Saraswathy 49 / F 24 162 / 98 288 205 45 38 192 95 19
28 Rajakumari 44 / F 24 160 / 100 292 198 49 40 195 99 20
29 Arockiyam 47 / m 26 160 / 90 282 196 46 46 204 101 21
30 Joseph 44 / m 27 164 / 94 272 204 47 50 203 116 20
31 Mariammal 49 / F 24 150 / 92 278 196 45 48 201 106 19
32 Saritha 47 / F 23 156 / 94 274 194 49 46 195 108 18
33 Govindan 44 / m 25 158 / 92 278 191 48 40 197 102 20
34 Rajathi 48 / F 23 160 / 90 282 192 42 42 191 102 21
S.No. Name BMI
T.cholesterol 
mg/dl
LDLC 
mg/dl
HDLC 
mg/dl
VLDLC 
mg/dl
TGL 
mg/dl
FBS 
mg/dl
S.insulin 
µU/ml
1 Lakshmi 44 / F 24 160 / 90 132 107 41 49 108 110 20
2 Mani 46 / m 26 154 / 90 121 111 36 52 112 98 16
3 Jayaraman 46 / m 25 160 / 100 112 108 42 51 123 85 15
4 Baskaran 45 / m 24 170 / 90 128 112 42 48 111 94 17
5 Kasi 44 / m 25 160 / 90 126 98 51 46 124 104 18
6 Pitchai 45 / m 24 170 / 110 132 100 54 45 112 106 17
7 Manickam 45 / m 24 150 / 100 127 102 48 49 119 98 19
8 Rathnam 46 / m 25 152 / 98 122 92 46 40 118 96 20
9 Jaya 44 / F 22 156 / 92 128 96 45 46 112 102 14
10 Nagammal 46 / F 23 158 / 94 112 98 49 50 108 104 16
11 Kuppusamy 46 / m 26 152 / 96 124 95 47 58 110 92 18
12 Sivaraman 45 / m 24 162 / 90 121 94 48 52 106 88 17
13 Surnammal 46 / F 21 152 / 100 120 98 45 54 110 94 19
14 Ranganayaki 47 / F 21 156 / 98 136 102 46 58 108 96 16
15 Vijayalakshmi 43 / F 22 162 / 100 120 106 48 48 112 98 17
16 Parvathi 46 / F 21 158 / 98 128 101 47 51 104 89 18
17 Sarasvathy 45 / F 21 156 / 102 132 88 48 42 116 98 18
MASTER CHART- CONTROL GROUP
Age/Sex
SBP/DBP 
mmhg
S.No. Name BMI
T.cholesterol 
mg/dl
LDLC 
mg/dl
HDLC 
mg/dl
VLDLC 
mg/dl
TGL 
mg/dl
FBS 
mg/dl
S.insulin 
µU/ml
Age/Sex
SBP/DBP 
mmhg
18 Laksmanan 46 / m 24 162 / 98 128 89 42 46 119 102 19
19 Jyothi 44 / F 22 154 / 98 136 92 41 50 108 96 17
20 Madhavan 45 / m 24 164 / 100 122 78 39 48 106 104 20
21 Rathnammal 46 / F 23 168 / 100 112 79 49 38 105 94 18
22 Subramanian 45 / m 21 170 / 100 108 92 45 44 116 88 16
23 Vinayagamurthy 46 / m 24 160 / 98 118 91 44 40 118 95 20
24 Ragavan 47 / m 23 150 / 90 126 94 40 46 112 94 19
25 Sankaran 44 / m 22 152 / 96 114 88 42 38 106 88 18
26 Chandra 44 / F 21 156 / 100 122 97 48 54 119 96 19
27 Indra 46 / F 22 160 / 90 130 102 47 49 121 98 19
28 Krishnamurthy 46 / m 24 154 / 100 126 88 51 48 118 90 17
29 Pushpa 45 / m 22 152 / 90 118 86 41 52 112 98 15
30 Shanmugam 45 / F 23 162 / 100 128 88 42 38 116 102 20
31 Shekar 46 / m 22 156 / 100 124 92 48 42 115 94 16
32 Arumugam 45 / m 21 152 / 98 128 94 47 48 109 98 18
33 Vel Murugan 46 / m 22 160 / 100 119 93 26 36 112 98 19
34 Ganesan 47 / m 23 162 / 98 122 95 42 44 115 88 18
BMI - Body Mass Index LDLC - Low Density Lipoprotein Cholesterol
SBP - Systolic Blood Pressure HDLC - High Density Lipoprotein Cholesterol
DBP - Diastolic Blood Pressure VLDLC - Very Low Density Lipoprotein Cholesterol
TGL - Triglycerides FBS - Fasting Blood Sugar
Experimental Group          
(34)
Control Group
 (34)
Age 45 ± 4 43 ± 3
Males 31 31
Females 13 13
BMI 27.3 ± 12 27.5 ± 2.1
SBP 154 ± 16 146 ± 24
DBP 100 ± 12 94 ± 8
T. Cholesterol 280 ± 20 140 ± 20
LDL 180 ± 20 110 ± 20
HDL 45 ± 10 40 ± 10
VLDL 40 ± 5 35 ± 15
TGL 220 ± 20 120 ± 20
FBS 106 ± 6 96 ± 6
Fasting Insulin 20 ± 5 18 ± 5
Table 1:
     Anthropometrical, Clinical and  Biochemical 
characters of volunteers
0mon 1 mon 2mon 3mon 4mon 5mon 6mon 7mon 8mon 9mon 10 mon 11mon
T. cholesterol 2.80 ± 20 276 ± 18 270 ± 16 260 ± 15 256 ± 16 248 ± 18 240 ± 16 234 ± 12 226 ± 11 218 ± 13 212 ± 12 208 ± 10
HDL 45 ± 10 45 ± 12 46 ± 12. 46 ± 13 47 ± 12 48 ± 16 48 ± 8 49 ± 11 50 ± 14 50 ± 10 51 ± 13 51 ± 11
LDL 180 ± 20 178 ± 18 17 ± 12 172 ± 11 172 ± 12 168 ± 18 166 ± 10 164 ± 8 160 ± 12 160 ± 8 158 ± 10 152 ± 8
VLDL 40 ± 5 40 ± 3 40 ± 2 39 ± 6 39 ± 5 39 ± 6 39 ± 5 39 ± 4 39 ± 2 39 ± 4 39 ± 3 39 ± 4
TGL 220 ± 20 218 ± 18 218 ± 16 214 ± 10 214 ± 8 216 ± 8 212 ± 10 210 ± 11 210 ± 12 206 ± 6 204 ± 8 204 ± 8
FBS 106 ± 6 106 ± 5 105 ± 3 103 ± 4 103 ± 3 101 ± 4 98 ± 5 98 ± 6 96 ± 5 93 ± 4 92 ± 5 90 ± 3
    Table 2:           Values of Blood parameters of Experimental Group 
12mon
202 ± 12
52 ± 12
148 ± 12
39 ± 3
202 ± 6
88 ± 4
                    Table 3:             Values of Blood parameters of Control Group 
0mon 1mon 2mon 3mon 4mon 5mon 6mon 7mon 8mon 9mon 10 mon 11mon 12mon
T. cholesterol 140 ± 20 138 ± 8 136 ± 16 134 ± 15 132 ± 15 130 ± 16 128 ± 8 125 ± 10 123 ± 8 120 ± 12 117 ± 6 115 ± 6 112 ± 18
HDL 40 ± 10 40 ± 8 41 ± 9 41 ± 7 41 ± 5 42 ± 6 42 ± 7 42 ± 7 42 ± 6 43 ± 8 43 ± 9 43 ± 8 44 ± 9
LDL 110 ± 30 110 ± 12 108 ± 18 108 ± 16 108 ± 14 106 ± 12 106 ± 13 106 ± 13 102 ± 11 100 ± 18 98 ± 16 97 ± 10 95 ± 13
VLDL 35 ± 15 35 ± 9 35 ± 8 35 ± 7 35 ± 8 35 ± 10 35 ± 10 35 ± 8 35 ± 12 35 ± 14 35 ± 11 35 ± 6 35 ± 8
TGL 120 ± 20 120 ± 11 120 ± 8 119 ± 12 120 ± 14 118 ± 12 119 ± 8 116 ± 15 118 ± 8 118 ± 11 110 ± 12 116 ± 12 116 ± 13
FBS 96 ± 10 96 ± 8 94 ± 6 94 ± 5 92 ± 8 94 ± 8 94 ± 5 92 ± 6 92 ± 9 88 ± 8 90 ± 7 90 ± 8 90 ± 6
Table 4:
S. insulin 
initial value
S. insulin end 
value
Homeostasis model 
assessment of insulin 
resistance 2-IR 
(initial value)
HOMA - 2 IR end 
value
Exp Group 20 ± 5 18 ± 3 4.3 ± 0.5 3.7 ± 0.4
Control Group 18 ± 5 18 ± 5 4.3 ± 0.3 4.3 ± 0.2
Showing serum insulin and HOMA-IR 2 values of different group
